CA-ARRCUS
26.2.2024 09:01:34 CET | Business Wire | Press release
Arrcus, the hyperscale networking software company and a leader in core, edge, and multi-cloud routing and switching infrastructure, announces the enhancement of its ACE-AI platform to address the growing demand for unified networking fabric for distributed AI workloads.
As AI workloads become increasingly distributed, driven by economic considerations and application requirements, Arrcus ACE-AI is a platform designed to seamlessly network them across various locations and deliver applications at the edge, with high speed and lossless connectivity. The emerging federated learning model for AI allows multiple entities to collaboratively train a model with decentralized data. Training models may be executed in hyperscale environments while inference models may be executed at the edge for various use cases. Arrcus recognizes the need for a unified networking fabric that interconnects these workloads, regardless of where they may reside. Modern data center applications demand high throughput (400-800Gbps) and ultra-low latency (< 10μs per hop), and Arrcus ACE-AI meets these demands while minimizing CPU overhead.
"The future of AI lies in its ubiquity, and Arrcus has built the industry’s most flexible and intelligent fabric that connects and orchestrates distributed AI workloads,” said Shekar Ayyar, Chairman and CEO of Arrcus. “With the enhanced ACE-AI platform, we are giving enterprises and service providers the power to unlock the full potential of AI, across clouds, data centers, and the edge."
Emerging artificial intelligence, high-performance computing, and storage workloads pose new challenges for large-scale datacenter networking. Arrcus addresses these challenges by supporting new features that build a lossless Ethernet fabric, including RoCEv2, PFC, ECN, ETS, AR, Dynamic Load Balancing, and Global Load Balancing.
One of the significant challenges in achieving high-performance networking for AI workloads is the limitation of traditional TCP/IP stacks at such speeds due to their high CPU overhead. Arrcus addresses this challenge by incorporating RDMA (Remote Direct Memory Access) technology, which offloads transport communication tasks from the CPU to hardware, providing direct memory access for applications without involving the CPU. The second version of RDMA over Converged Ethernet (RoCE-v2) further enhances the protocol with UDP/IP headers with routing.
In addition to these feature enhancements, Arrcus is also pleased to announce support for new industry-leading platforms from Broadcom that are state-of-the-art 800G switching platforms – Tomahawk5, Jericho3, Ramon3 – in partnership with device manufacturers like Ufispace and Edgecore.
"Broadcom is very excited to collaborate with Arrcus to deliver industry-leading switching solutions that are optimized to meet the performance demands of next-generation AI workloads. Together, Arrcus and Broadcom are enabling customers to build high-performance, scalable, and intelligent data center networks,” said Ram Velaga, senior vice president and general manager, Core Switching Group, Broadcom.
Key features that make Arrcus the industry’s leading networking platform for AI:
- High-Performance Networking for AI: Support for industry-leading hardware with Broadcom switches like Tomahawk5 and Jericho3-AI, RoCEv2, SmartNICs from NVIDIA and Intel, and enabling ultra-low latency (< 10μs per hop) and high throughput (400-800Gbps) required by modern AI applications.
- Multi-Cloud Cost Optimization: Enhanced FlexMCN with Egress Cost Control (ECC) technology empowers users to analyze, allocate, and dynamically route traffic across clouds for optimal cost efficiency, reducing egress charges by up to 15%.
- Automated 5G Network Slicing for AI: Integration of SRv6 Mobile User Plane (MUP) and Flex Algo enables automated delivery of AI applications with 5G network slicing, streamlining service deployment and resource allocation.
- End-to-End Network Visibility with ArcIQ: New ArcIQ capabilities extend real-time network insights to user equipment, providing actionable data for proactive incident management.
With these latest capabilities and dedication to innovation, Arrcus is enabling organizations to break through the limitations of traditional networking and embrace the full potential of distributed AI. The enhanced ACE-AI platform signifies a pivotal step in building the intelligent fabric for the AI-powered future.
Additional Resources
- Arrcus Unveils Groundbreaking ACE-AI Networking Solution
- Arrcus Delivers Next Generation of High-Performance, Zero-Trust Networking for Datacenters Enabled by NVIDIA BlueField
About Arrcus
Arrcus was founded to enhance business efficiency through superior network connectivity. The Arrcus Connected Edge (ACE) platform offers best-in-class networking with the most flexible consumption model at the lowest total cost of ownership. The Arrcus team consists of world-class technologists who have an unparalleled record in shipping industry-leading networking products, complemented by industry thought leaders, operating executives, strategic partners and top-tier VCs. The company is headquartered in San Jose, California, with offices in Bangalore, India, and Tokyo, Japan. For more information, go to www.arrcus.com or follow @arrcusinc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240226461853/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
